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Introduction
Despite a few global regions with increased incidence, cancers 
of the biliary tract remain a rare entity. Cholangiocarcinoma 
has been referred to as an ‘orphan’ cancer, given its relative 
infrequency in the Western population. Most patients are 
diagnosed at an advanced disease stage which contributes 
to a 5-year survival that is less than 10% (1). Although 
cholangiocarcinoma remains relatively rare, the incidence of 
intrahepatic cholangiocarcinoma has been rising worldwide 
over the past decade (2) and thanks to the relentless advocacy 
efforts of the Cholangiocarcinoma Foundation and focused 
research from a few investigators, advances in the molecular 
description of the entity have recently been seen (3). The 
potential for targeted therapies to address several mutational 
changes, added to the new discoveries in immunotherapy 
has led experts to rethink the entity of biliary cancers and to 
view the disease through a new lens as summarized herein. 
This communique summarizes the thoughts of some of the 
world’s experts in biliary cancer as they challenged each 
other in debates and lecture discussions on multi-varied 
subjects as part of the Third Annual Cholangiocarcinoma 
Foundation Meeting that was held in Salt Lake City, Utah 
between February 3 and 5, 2016.
Surgical resection and liver transplantation 
Surgical resection of cholangiocarcinoma remains the only 
potentially curable therapy and is rarely feasible except 
in extrahepatic cholangiocarcinoma where tumors are 
commonly located at or near the junction of the left and 
right hepatic ducts. This location at the biliary confluence 
near the bifurcation of the portal vein and the right hepatic 
artery accounts for the challenges of adequate surgical 
resection. Even in the absence of distant spread, achieving 
negative bile duct margins, leaving behind adequate liver 
remnant function, and maintaining adequate portal and 
arterial inflow to the liver remnant is a difficult task. When 
resection is being considered, the goal is to completely 
remove all tumor tissue (R0 resection) maintaining an 
adequate liver remnant. An incomplete (R2: grossly involved 
margin) resection is probably futile and any potential benefit 
too small to justify the surgical risk. The biliary extent of 
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the tumor should allow a margin negative resection and 
permit technically feasible reconstruction of the biliary 
tree, with an adequate remnant liver volume, usually at 
least 30% of the total liver volume. Studies examining 
the outcomes of patients with cholangiocarcinoma who 
undergo surgery with curative intent find a median overall 
survival of 34 months. Several prognostic factors may 
identify subgroups of patients with better survival. In 
patients with R0 resection, median overall survival rates of 
60 to 65 months are reported. In addition, a negative lymph 
node status, well-differentiated tumor grade, and papillary 
phenotype are independent predictors of favorable survival. 
Unfortunately the high rate of recurrence in the remnant 
liver is associated with a 5-year survival of only 20–30% in 
most series of patients undergoing partial hepatic resection. 
This has led to investigation of liver transplantation as a 
strategy for curative therapy for this dismal disease. Current 
reports using neoadjuvant chemoradiation in conjunction 
with liver transplantation demonstrate 5-year survival 
rates of 50–70% in highly selected patients with hilar 
cholangiocarcinoma (4). Current criteria include use of this 
approach in patients with unresectable tumors less than 
3 cm in greatest dimension, in the absence of intrahepatic 
or regional nodal involvement, and in whom transperitoneal 
biopsies have not been performed. While promising, this 
approach can only be utilized in highly selected patients. 
Improved diagnostic studies and earlier detection are greatly 
needed to allow more patients to be eligible for curative 
therapy. Intrahepatic cholangiocarcinoma is generally 
considered a contraindication for liver transplantation at 
most centers, however results for patients with solitary 
tumors less than 3 cm in size, in the setting of underlying 
cirrhosis, suggest that this therapy has similar success rates 
to transplantation in patients undergoing transplant for 
hilar tumors. While efforts continue to help better define 
the role of transplantation, future studies should also focus 
on refining surgical techniques, expanding minimally 
invasive approaches, and finding better adjuvant treatments 
to reduce the high recurrence rate.
Adjuvant therapy for cholangiocarcinoma: 
different views
The role of adjuvant therapy following curative resection 
of cholangiocarcinoma is uncertain. While some cancer 
characteristics have been identified which clearly increase 
the risk for tumor recurrence (1)—multifocality, lymph node 
and margin-positive disease—the rarity and heterogeneity 
of the disease has made the conduct of classic randomized 
studies very difficult. Therefore adjuvant therapy guidelines 
reflect consensus statements and literature reviews; for 
example, patients in whom adjuvant therapy did not provide 
a significant improvement in survival (5). Within this report, 
a subset analysis suggested that patients who were left with 
positive lymph nodes or R1 resection margins derived the 
most benefit for adjuvant chemoradiation or chemotherapy. 
But the applicability of this observation has the limitation of 
any retrospective data set, reflecting the lack of consistency 
in the extent and details of surgery. A very small number of 
intrahepatic cholangiocarcinoma cases were included in this 
meta-analysis and therefore the benefit of adjuvant therapy 
in intrahepatic cholangiocarcinoma is unproven. In cases 
of extrahepatic (hilar) cholangiocarcinoma, the Mayo clinic 
experience has highlighted the role of liver transplantation 
in those with unresectable disease (4). While there are a 
range of opinions, until there are better data available, the 
presented meta-analysis by Horgan et al. makes reasonable 
and rationale recommendations for managing patients.
Similarly, the role for radiation for cholangiocarcinoma 
has come under scrutiny; recommendations largely stem 
from observations that radiotherapy does not affect survival 
in pancreatic cancer, which is the data source behind much 
of the rationale. However, larger scale genomic studies 
confirm that cholangiocarcinoma has much lower rates 
of mutant KRAS, which preclinical studies have shown 
confers radio-resistance (6-8). This observation is backed 
by clinical observations that mutant KRAS tumors have 
worse outcomes than wild type KRAS in rectal cancer, 
lung stereotactic body radiation therapy (SBRT), and 
liver SBRT. Additionally, local control, particularly in 
extrahepatic cholangiocarcinoma, appears to be a dominant 
failure pattern, and associated with quality of life issues. 
More data that supports the role of radiation include the 
recently published phase II study of protons in inoperable 
intrahepatic cholangiocarcinoma demonstrating 2-yr local 
control of 95% (9). Additionally, a study by Southwest 
Oncology Co-operative Group (SWOG) evaluating 
gemcitabine plus capecitabine followed by chemoradiation 
demonstrated a much lower local failure than historical 
surgical series (10). Further formal evaluations of the role of 
radiation in cholangiocarcinoma are needed.
In summary,  adjuvant treatment with systemic 
chemotherapy or chemoradiation is still not standard of 
care for most patients with cholangiocarcinoma. Patients 
with multifocal, node or margin positive disease should be 
considered for clinical trials of adjuvant therapy. Ongoing 
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international trials will offer insight in this regard. The 
recent SWOG phase II trial enrolled patients with 
extrahepatic cholangiocarcinoma or gallbladder cancer who 
were treated with systemic chemotherapy (gemcitabine 
plus capecitabine) followed by chemoradiation (5). A total 
of 79 eligible patients were treated; the 2-year survival was 
65%, whereas it was 67% and 60% in R0 and R1 patients, 
respectively. Median overall survival was 35 months. This 
regimen is therefore considered as effective as an adjuvant 
approach. The same group has planned a randomized 
controlled trial for extrahepatic cholangiocarcinoma. 
Targeted therapeutics represents a promising strategy for 
advanced cholangiocarcinoma. Recent genomic sequencing 
studies have identified a host of genetic aberrations that are 
potentially targetable. These include ERBB2, IDH1, FGFR 
and B-RAF mutations (6,11,12). 
Systemic therapy: one-size fits all or custom-made 
therapy?
In the setting of advanced (locally advanced, recurrent or 
metastatic) biliary tract cancers, systemic chemotherapy with 
gemcitabine plus cisplatin has become the reference regimen, 
based on the results of the ABC-02 study (13). In this study, 
patients who met standard eligibility criteria (e.g., performance 
status 0–1, baseline bilirubin level ≤1.5× upper limit of normal 
and adequate renal function) were included as long as the 
cancer was biliary in origin. While it is widely acknowledged 
that within the term “cholangiocarcinoma” there are different 
subgroups of patients based on anatomy—intrahepatic, 
extrahepatic and gallbladder—as well as on different molecular 
signatures (14), an assessment of the magnitude of benefit 
of gemcitabine plus cisplatin was constant in ABC-02 across 
the different diagnoses, an effect maintained when Japanese 
patients were also evaluated (15). This confuses the question 
of whether to look at the entire population or at subsets when 
exploring new treatment options.
The establishment of standard chemotherapy regimens 
for cholangiocarcinoma is a recent phenomenon (the first 
effective cholangiocarcinoma regimen was identified in 
2010 vs. the first regimens for colorectal cancer established 
in the 1950s). Fluoropyrimidines (5-FU and capecitabine) 
along with gemcitabine and platinum compounds appear 
to be active. However, to date, no biomarkers have been 
identified to predict who will respond to chemotherapy, and 
the pressures to find active therapies are balanced against 
the challenges of improving outcomes in patients who often 
have disease courses complicated by compromised liver 
function and infections, for example. 
On the other hand, there are “actionable” targets in the 
biliary tract. The first generation of studies has targeted the 
epithelial growth factor receptor. Despite the encouraging 
results of the early phase II, single arm study of cetuximab 
in addition to the gemcitabine/oxaliplatin combination 
(GemOx) (16), four randomized studies [adding cetuximab 
(two studies) (17,18) erlotinib (19) or panitumumab (20) 
respectively to the GemOx regimen] have now failed to 
demonstrate a PFS or OS improvement over chemotherapy 
alone, highlighting the need for randomized trials to 
truly evaluate the potential benefit of novel agents. 
Retrospectively, it will be important to identify, if possible, 
if there were any subgroups of patients who did derive 
benefit within the whole study population of those studies. 
At present, chemotherapy as a “one-size-fits all” remains 
one of the cornerstone of treatment (along with surgery 
and radiotherapy); much as it remains in other cancers 
such as breast cancer, colorectal cancer and lung cancer 
where targeted therapies are also being increasingly used. 
However, advances in DNA sequencing technologies 
have enabled the identification of common tumor 
mutations in biliary tract cancers, including IDH1, IDH2, 
FGFR2, mismatch repair proteins, and ERBB2 (21,22). 
The frequency of certain mutations is associated with 
tumor location, with significantly different incidences for 
intrahepatic, extrahepatic, and gall bladder sites of cancer. 
The genetic heterogeneity between individual biliary tract 
cancers suggests that treatment should be individualized, 
or “custom-made”, according to tumor mutation status 
in some cases. In support of this hypothesis, clinical trials 
of several novel targeted agents for genetically-defined 
subsets of biliary tract cancers show promising efficacy, 
including the IDH1 inhibitor, AG-120, for IDH-1-mutant 
cholangiocarcinoma (23), the pan-FGFR inhibitor BGJ398 
for intrahepatic cholangiocarcinoma harboring FGFR2 
gene fusions or other FGFR pathway aberrations (24), 
and the immune checkpoint inhibitor pembrolizumab 
for biliary tract cancers with defects in mismatch repair 
genes (25). These exciting data support ongoing efforts to 
better define anatomic, molecular, and genetic subsets of 
biliary tract cancers for stratification and enrichment in 
clinical trials of targeted therapies to identify patients most 
likely to respond, so that we may move towards custom-
made therapy for patients suffering from this complex and 
heterogeneous family of cancers. 
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Molecular profiling of biliary cancers: the future 
of therapy
Whole exome and transcriptome sequencing of biliary tract 
cancers has provided key insights into the heterogeneity 
of molecular alterations among cancers arising at different 
sites along the biliary tract and a strong rationale for the 
development of molecularly targeted therapies. While 
FGFR2 gene fusions and IDH1/2 and BAP1 mutations 
are found in intrahepatic cholangiocarcinoma, PRKACA/
PRKACB fusions, ELF3 and ARID1B mutations occur 
preferentially in extrahepatic cholangiocarcinoma while 
aberrations in ERBB2/3, EGFR, PTEN and mutations in 
TERT promoter gene have been described in gallbladder 
cancers (26). A poor prognosis subtype characterized by 
high mutational load and increased immune checkpoint 
activity has been identified across all sites, and may predict 
for response to immune checkpoint inhibitors. Optimally, 
patients will be selected for targeted therapy based on 
molecular profiling. Ongoing clinical trials are evaluating 
the use of TRK, ALK and ROS-1 inhibitors in patients 
with NTRK or ROS-1 rearrangements, and FGFR 
inhibitors in patients with FGFR2 fusions, while inhibitors 
of IDH1/2 and ERBB2/3 are also in clinical development in 
genetically selected populations. The wealth of therapeutic 
targets identified by molecular profiling offers promise for 
integration of targeted therapy with chemotherapy, and 
hopes for a significant improvement in patient outcomes 
over the coming decade.
Based on the previous section, one may wonder 
if molecular profiling is justified for all patients with 
cholangiocarcinoma at this point in time. The end goal of 
tumor profiling is the application of personalized medicine 
to optimize therapeutic benefit and minimize toxicity or 
unnecessary exposure to side effects. The application of 
molecular profiling for the treatment of biliary cancers faces 
challenges related to the heterogeneity of the disease, the 
prioritization of targets as well as identification of driver 
alterations, the clonal evolution of cancer and several other 
microenvironment and stromal pressures which impact the 
biology of this cancer in a global manner. It has become 
clear that relevant therapeutic targets can be elucidated 
through molecular profiling such fusions in FGFR or 
mutations in IDH1 and amplifications in Her2. These 
continue to be relatively rare and vary based on the site of 
origin of the biliary cancer (intra-versus extrahepatic). To 
optimize the application of molecular profiling, it would be 
prudent to follow careful algorithms to prioritize molecular 
alterations, to account for tumor heterogeneity and clonal 
evolution (possibly through liquid biopsies), and to account 
for the effect of the epigenome and the microenvironment 
on the tumor. Lastly, emerging research suggests that 
integrative molecular analysis approaches can help to 
classify biliary cancers into specific subgroups with distinct 
molecular signatures that are associated with prognosis and 
that may in turn offer opportunities for tailored treatment 
approaches aimed at more global signatures. In summary, 
there is jewel in the haystack as some molecular alterations 
may offer excellent therapeutic opportunities but advancing 
the treatment of this complex disease also requires a more 
global understanding of the biology and likely combinations 
of therapies.
A special type of intrahepatic cholangiocarcinoma: 
fluke-worm related cholangiocarcinoma
Liver flukes are the foodborne parasites dwelling in the 
biliary tract. Based on epidemiologic data and animal 
models, the infection of two liver flukes, Opisthorchis 
viverrini and Clonorchis sinensis, is strongly associated with 
intrahepatic cholangiocarcinoma in humans. People get 
infected with liver flukes by eating raw freshwater fish, and 
it has been hypothesized that chronic fluke infection and 
both endo- and exogenous nitrosamine formation causes 
intrahepatic cholangiocarcinoma in Northeastern Thailand, 
with the world’s highest incidence of the disease. Although, 
the “top-down” mass anti-helminthic therapy could 
lower the infection prevalence in the past two decades, 
re-infection is still the major challenge for intrahepatic 
cholangiocarcinoma prevention. Therefore, researchers 
at Khon-Kaen University have initiated a “bottom up” 
strategy to establish a durable healthy ecosystem led by the 
community. Following the successful pilot project, it has 
been expanded to other areas in Northeastern Thailand (27). 
Although the clinical presentations of fluke-associated 
intrahepatic cholangiocarcinoma are similar to non-
fluke associated ones, fluke-associated intrahepatic 
cholangiocarcinoma tend to occur at the hilar or perihilar 
bile ducts. Molecular differences between fluke- and non-
fluke associated with intrahepatic cholangiocarcinoma 
have been identified in mRNA expression, gene mutation 
and microRNA expression profiles. Currently, there is no 
difference in management of fluke- and non-fluke associated 
intrahepatic cholangiocarcinoma. However, based on 
molecular differences, we can look forward to different 
treatment for these two entities.
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The potential for immunotherapy in biliary tract 
cancer
Immune checkpoint inhibition leads to durable tumor 
control and shrinkage in a subset of patients with a variety 
of advanced malignancies. Immune checkpoint blockade 
has translated into a significant overall survival advantage 
in comparison to established therapies in some metastatic 
solid tumors (28). A critical question is whether immune 
checkpoint blockade will lead to clinical benefit and improved 
survival in patients with cholangiocarcinoma. Emerging 
preclinical data suggest that a subset of biliary tract cancers 
are recognized by the immune system but undergo a complex 
process of immune editing, which allows biliary tract cancers 
to evade an anticancer immune response. Furthermore, 
stromal factors, such as carcinoma associated fibroblasts, 
may exclude and exhaust effector T lymphocytes, leading to 
biliary tract cancers’ immune privilege. Preliminary clinical 
data indicate that some patients with biliary tract cancers 
respond to immune checkpoint blockade and several studies 
are now planned or ongoing to define the role of this novel 
therapeutic approach. 
CCA genetics and cancer detection
The major identified risk factors for CCA are underlying 
inflammatory disorders, and transcriptional profiling of 
intrahepatic CCA has revealed a subset of cancers with 
an inflammatory STAT3 signature. In addition, genome 
sequencing studies suggest that chromatin modifiers are 
frequently disrupted in this disease suggesting intrahepatic 
CCA may be a disease of epigenetic chromatin modification. 
Gain-of-function mutations in the isocitrate dehydrogenase 
(IDH) gene are one potential mechanism for epigenetic 
dysregulation, as the mutant enzyme catalyzes the formation 
of the oncometabolite 2-hydroxyglutaric acid, which 
inhibits histone demethylases. Mutations in IDH are rare 
in most epithelial tumors but relatively common in CCA, 
and trials with IDH inhibitors for patients with activating 
mutations are underway. Fibroblast growth factor receptor 
2 (FGFR2) fusions are also common in intrahepatic CCA, 
and recent studies suggest that the pan-FGFR inhibitor 
BGJ398 may be active in treating cancers with these gene 
fusion aberrations (29). In contrast to intrahepatic CCA, 
PRKACA and PRKACB fusion genes are common in 
perihilar CCA and presumably are targetable. CCA is also a 
highly desmoplastic cancer with a rich stroma characterized 
by cancer associated fibroblasts (CAF). Preclinical data 
suggest that CAF are susceptible to a class of drugs termed 
BH3 mimetics and that targeting CAF with these agents 
may have an anti-tumor effect in CCA (30). 
The analysis of 38 CCA samples from The Cancer 
Genome Atlas project (TCGA), including mutations, 
methylation, copy number, RNA, miRNA, and protein 
platforms was reported (Lawrence N. Kwong, new 
unpublished data). A meta-analysis of all published 
sequencing data to date in >500 fluke-negative intrahepatic 
cholangiocarcinoma samples revealed potential mutual 
exclusivity of PIK3CA and TP53 mutations as well as KRAS 
and IDH mutations. Should these exclusivities hold up in 
larger cohorts, they could form a partial basis for classifying 
cholangiocarcinoma with therapeutic implications given the 
rapid development of PI3K pathway, MAPK pathway, and 
IDH inhibitors? The TCGA analysis identified a distinct 
cross-platform signature of IDH mutant samples which 
included specific copy number profiles, methylation profiles, 
and most critically, expression profiles that were enriched 
for increased oxidative phosphorylation and decreased 
chromatin modifier signatures. Moreover, several IDH-wild 
type samples were found to resemble IDH mutant samples 
in both expression and copy number profile. Overall, 
these studies provide an initial step towards identifying 
clinically-relevant molecular classifications of intrahepatic 
cholangiocarcinoma with therapeutic implications given 
recent and ongoing efforts to develop inhibitors of oxidative 
phosphorylation epigenetic modifiers.
Using the paradigm of pancreatic cancer, another 
highly lethal malignancy for which most patients are 
unresectable at the time of diagnosis, early detection of 
cholangiocarcinoma could employ the same leukopheresis 
to enrich the number of cells recovered. Rhim described 
efforts to detect tumor-associated DNA sequences in 
patient-derived material, including circulating tumor cells 
(CTCs), exosomes, and as cell free DNA in the plasma. 
Digital droplet PCR, which allows for highly sensitive 
amplification of DNA when a template is present, has 
been adapted for this so that approximately 250 different 
amplicons of interest can be amplified for sequencing. 
Metabolism and epigenetics
With respect to mutant IDH, metabolism is important. 
By focusing on metabolic pathways that are limiting for 
the proliferation of cancer cells in different environmental 
and tissue contexts, Vander Heiden found that nucleotide 
synthesis is often limiting, and that the tumor cell of origin 
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and tissue microenvironment dictate how cells generate 
nucleotides. For example, in many tumors access to 
oxygen or other electron acceptors limits the production 
of aspartate, which is necessary for purine, pyrimidine and 
protein synthesis. Further underscoring the importance of 
the environment in dictating cell metabolism, tumor cells 
grown in vitro predominantly rely on glutamine as a carbon 
source while many of the same cells growing in vivo rely less 
on exogenous glutamine as a fuel source.
At the interface of epigenetics and genetics, Whetstine 
presented data showing that in addition to changes in 
chromatin, the lysine demethylase Jmjd2a (KDM4a) could 
also drive changes in copy number in specific regions of the 
genome. Surprisingly, these changes in copy number were 
reversible. Whetstine proposed that reversible copy number 
changes may be a mechanism employed by normal cells 
to respond to stress (hypoxia in particular) and that cancer 
cells may co-opt the process during progression. 
Animal models
The liver is well known for its regenerative capacity, which 
under normal circumstances is mediated by the replication of 
existing cells. What has become clear over the last few years 
is that many forms of liver injury are also accompanied by 
substantial cellular plasticity, whereby hepatocytes become 
converted into cells with many or most cholangiocyte 
features. This phenomenon of cellular plasticity was touched 
upon in several talks from the last session, which dealt with 
the use of preclinical models of CCA.
Cholangiocarcinoma can originate from hepatocytes 
in mice (31). Hepatocytes were labeled and then exposed 
to activated Notch and Akt signaling. This resulted in the 
development of tumors with histological and molecular 
features of intrahepatic cholangiocarcinoma. Because the 
tumor cells bore the hepatocyte lineage label, this provided 
unambiguous evidence that the tumors had arisen from 
hepatocytes, and work from other groups has supported this 
finding (32). Willenbring went on to discuss work regarding 
the role of plasticity in normal liver regeneration, showing 
that hepatocytes can also give rise to biliary cells in a genetic 
model of bile duct paucity.
Data also suggest that intrahepatic cholangiocarcinoma 
can also arise from cholangiocytes (33). Forbes used a strain 
of mice in which Cre recombinase could be activated in 
cholangiocytes in a tamoxifen-inducible manner (CK19-
CreER). Using this strain, in combination with a lineage 
marker, his group deleted p53 specifically in the biliary 
compartment. When these manipulations were combined 
with administration of the carcinogen thioacetamide (TAA), 
they developed intrahepatic cholangiocarcinomas over a 
6-month period, demonstrated a clear biliary origin of the 
tumors. Based on these studies, it appears that intrahepatic 
cholangiocarcinoma can arise from either cholangiocytes 
or hepatocytes in the right context. Forbes also showed 
data regarding the role of Wnt and Notch signaling in 
CCA pathogenesis. Analysis of human tissue revealed 
that the stromal macrophages surrounding intrahepatic 
cholangiocarcinomas express Wnt ligands. Moreover, the Wnt 
pathway activity progressively increases during pre-malignant 
progression, suggesting that Wnt pathway inhibitors (e.g., 
inhibitors of the Wnt regulator porcupine) could have 
therapeutic benefit in CCA.
Obviously there are pros and cons to the various model 
systems. In particular, one may ask if the genetically 
engineered models and patient-derived xenograft (PDX) 
models adequately capture the complex intra- and inter-
tumoral biology of CCA that will be necessary to move 
therapies forward. Andersen suggested that increased 
access to patient samples was the best way to understand 
the biology and therefore generate progress, and to this 
end described a number of efforts underway to molecularly 
characterize human CCA.
Saha reviewed the work of the group to create a 
genetically engineered mouse model of CCA which 
incorporates mutations in IDH and Kras (34) and then went 
on to describe a high-throughput screen in which a panel 
of CCA cell lines was pitted against a library of clinically-
relevant compounds. Comparing the responses of the CCA 
cell lines to those of >600 cell lines derived from other 
solid tumor types revealed that CCA lines bearing IDH 
mutations had a distinct response profile. In particular, 
mutant CCA cells exhibited extreme sensitivity to a class of 
kinase inhibitors. By applying CRISPR/Cas9-based genome 
editing, the key mediators of drug sensitivity were defined, 
enabling the creation of a new clinical trial for intrahepatic 
cholangiocarcinoma patients with IDH mutations.
CCF grant recipient talks
In 2015, the CCF awarded its first research fellowships—
one-year grants to junior investigators to pursue CCA 
research and the first afternoon session featured four short 
talks by the first cohort of Fellowship recipients. Allyson 
Merrell began by speaking about the cellular origins of 
CCA, an area of some controversy in the field. Because 
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CCA exhibits histological features of ducts, tumors were 
thought to arise from duct-lining cholangiocytes (or 
biliary epithelial cells). However, different laboratories 
have shown, using lineage tracing in the mouse, that both 
hepatocytes and biliary epithelial cells can give rise to CCA 
depending on the oncogenes used and other experimental 
details. Merrell is systematically testing different mutations 
in both cell types to clarify the connection between cell of 
origin, mutational spectrum, and resulting tumor type. As 
cellular plasticity is an important feature of normal liver 
injury, these findings may reflect a connection between 
the multiple cells of origin and the frequent mutation of 
epigenetic regulators in CCA. 
Next, Katsuyuki Miyabe spoke about his studies 
regarding fibroblast growth factor receptor (FGFR) gene 
family aberrations in CCA, hypothesizing that FGF 
receptor aberrations other than the known mutations in 
FGFR2 might play a pathogenic role. RNA sequencing of 
9 cases of CCA samples showed that several FGF ligands 
and FGF receptor 4 (FGFR4) are expressed at significantly 
lower levels when compared to 119 normal liver samples 
from the GTex database. Moreover, RNA sequencing has 
also detected new fusions of potential interest. Miyabe 
found that multiple FGFR inhibitors (ponatinib, dovitinib, 
BGJ398) inhibited the growth of LIV31 CCA xenografts 
(with FGFR fusions), with BGJ398 being the most potent. 
This xenograft model could be used in the future to select 
the FGFR inhibitor which works best for a given patient’s 
fusion. 
Daniela Sia provided further insight into the role of 
FGFR2 fusions in CCA. As prior work showed a novel 
FGFR2 fusion event (FGFR2-PPHLN1) in 16% of 
intrahepatic cholangiocarcinoma patients (35), Sia tested the 
impact of this aberration by injecting mice with FGFR2-
PPHLN1—expressing cells, showing enhanced tumor 
growth rates compared to mice injected with empty vector. 
The most dramatic effects were seen during the initial 
phase of tumor growth. Treatment of FGFR2-PPHLN1—
expressing HUCCT1 xenografts with a FGFR2 inhibitor, 
BGJ398, induced decreased tumor growth compared 
to the placebo group with no apparent signs of toxicity. 
Similar efficacy of BGJ398 was observed in vitro in cell lines 
expressing other FGFR fusion proteins, including FGFR2-
BICC1.
Chad Walesky described how he is using the zebrafish 
to study the influence of developmental pathways on CCA 
pathogenesis. Specifically, he is focusing on potential 
interactions between the Wnt/β-catenin pathway and 
hepatocyte nuclear factor 4 alpha (HNF4α), molecules 
that are involved in the development of the liver as well 
as CCA (35-40). Studies in the laboratory have shown 
that knockdown of HNF4α in the zebrafish leads to a 
reduction in hepatocyte differentiation while genetic or 
chemical increase in β-catenin results in a loss of HNF4α 
and a maintenance of cholangiocyte differentiation. Based 
on these findings, it is hypothesized that activation of 
β-catenin results in a loss of HNF4, causing hepatoblasts to 
preferentially differentiate into cholangiocytes. 
Conclusions
The work described herein gives an in-depth summary of 
the current approaches to treatment and translation for 
cholangiocarcinoma. This conference also brought together 
a broad collection of clinical and scientific investigators 
sharing the common goal of understanding and combatting 
cholangiocarcinoma. As exemplified by several of the talks, 
this type of fundamental understanding has already led to 
the development of patient-specific therapeutic approaches 
that can be tested in clinical trials. Other approaches, 
including immunotherapy,  are viewed with great 
excitement, but will require more of the same type of basic 
understanding for progress to be made. More importantly, 
it helps identify the unanswered questions and challenges 
which require cross-disciplinary collaboration and strong 
advocacy to resolve and overcome.
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